Literature DB >> 9725545

Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers.

N N Vachharajani1, W C Shyu, T J Chando, D W Everett, D S Greene, R H Barbhaiya.   

Abstract

Absolute oral bioavailability and disposition characteristics of irbesartan, an angiotensin II receptor antagonist, were investigated in 18 healthy young male volunteers. Subjects received [14C] irbesartan as a 30-minute intravenous infusion (50 mg), [14C] irbesartan orally as a solution (50 mg or 150 mg), or irbesartan capsule (50 mg). Irbesartan was rapidly and almost completely absorbed after oral administration, and exhibited a mean absolute oral bioavailability of 60% to 80%. Mean total body clearance was approximately 157 mL/min, and renal clearance was 3.0 mL/min. Volume of distribution at steady state was 53 L to 93 L, and terminal elimination half-life was approximately 13 to 16 hours. Hepatic extraction ratio was low (0.2). There were no major circulating metabolites, and approximately 80% of total plasma radioactivity was attributable to unchanged irbesartan. Regardless of route of administration, approximately 20% of dose was recovered in urine and the remainder in feces.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9725545     DOI: 10.1002/j.1552-4604.1998.tb04809.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  18 in total

1.  Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers.

Authors:  Shifen Gu; Hui Chen; Yinghai Qiu; Shaojun Shi; Fandian Zeng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2002

2.  CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population.

Authors:  Xiumei Hong; Shanchun Zhang; Guangyun Mao; Shanqun Jiang; Yan Zhang; Yunxian Yu; Genfu Tang; Houxun Xing; Xiping Xu
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

3.  PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions.

Authors:  Xiao-Hui Huang; Jun Li; Fu-Rong Qiu; Hai-Tang Xie; Ji-Han Huang; Jian-Chun Li; Qing-Shan Zheng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Oct-Dec       Impact factor: 2.441

4.  Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data.

Authors:  Venkata V Pavan Kumar; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

5.  The effects of age and gender on the pharmacokinetics of irbesartan.

Authors:  N N Vachharajani; W C Shyu; R A Smith; D S Greene
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 7.  Irbesartan: an updated review of its use in cardiovascular disorders.

Authors:  A Markham; C M Spencer; B Jarvis
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

Review 8.  Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Authors:  Katherine F Croom; Monique P Curran; Karen L Goa; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Irbesartan/Hydrochlorothiazide : in moderate to severe hypertension.

Authors:  Jamie D Croxtall; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.